Accentia Biopharmaceuticals Inc. (ABPI) Subsidiary Releases Positive Results for Clinical Trial of Non-Hodgkin’s Lymphoma Treatment
Biovest International Inc. (OTCBB: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals Inc. (NASDAQ:ABPI), today announced “highly encouraging” results for its controlled, pivotal phase 3 clinical trial of BiovaxID to treat the occasionally fatal blood cancer, indolent follicular non-Hodgkin’s lymphoma (NHL). "Although these results are blinded, this data shows two distinct populations in the study, with unequivocal evidence of a difference in disease-free survival among the two arms. This is in direct contrast to previous anti-NHL vaccine failures which showed little difference between the treatment arm and the control arm. Based on the similar pattern to our phase 2 data, we…